Tau immunotherapy targets transcellular propagation

Nature Reviews Drug Discovery

Volumn 12, Issue 12, 2013, Pages 904-905

  Flight, Monica Hoyos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HJ8 5; MONOCLONAL ANTIBODY HJ9 3; MONOCLONAL ANTIBODY HJ9 4; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL AGGREGATION; DRUG TARGETING; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOTHERAPY; LEARNING DISORDER; NEUROFIBRILLARY TANGLE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COGNITION DISORDERS; IMMUNOLOGY; METABOLISM; TAUOPATHIES;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; COGNITION DISORDERS; HUMANS; TAU PROTEINS; TAUOPATHIES;

EID: 84892989659     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4179     Document Type: Note

References (1)

1. Yanamandra, K. et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414 (2013)